<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: following risk factors could", fill: "#ef98aa"},
{source: "1: following risk factors could", target: "1: financial position", fill: "#ef98aa"},
{source: "1: financial position", target: "1: operations", fill: "#ef98aa"},
{source: "1: operations", target: "1: market value", fill: "#ef98aa"},
{source: "1: market value", target: "1: common stock", fill: "#ef98aa"},
{source: "1: following risk factors could", target: "4: development", fill: "#a57164"},
{source: "4: development", target: "4: inherently risky especially", fill: "#a57164"},
{source: "4: inherently risky especially", target: "4: been established", fill: "#a57164"},
{source: "4: development", target: "START_HERE", fill: "#a57164"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Disapprove</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Denounce or denigrate</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Collaborate</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_accounting">Financial accounting</a></td>
      <td>Financial accounting is the field of accounting concerned with the summary, analysis and reporting of financial transactions related to a business. This involves the preparation of financial statements available for public use.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Futures_contract">Futures contract</a></td>
      <td>In finance, a futures contract (sometimes called a futures) is a standardized legal contract to buy or sell something at a predetermined price for delivery at a specified time in the future, between parties not yet known to each other. The asset transacted is usually a commodity or financial instrument.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_Financial_Reporting_Standards">International Financial Reporting Standards</a></td>
      <td>International Financial Reporting Standards, commonly called IFRS, are accounting standards issued by the IFRS Foundation and the International Accounting Standards Board (IASB). They constitute a standardised way of describing the company's financial performance and position so that company financial statements are understandable and comparable across international boundaries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_public_corporations_by_market_capitalization">List of public corporations by market capitalization</a></td>
      <td>The following is a list of publicly traded companies having the greatest market capitalization. In media they are described as being the most valuable companies, a reference to their market value.Market capitalization is calculated from the share price (as recorded on selected day) multiplied by the number of outstanding shares.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fair_market_value">Fair market value</a></td>
      <td>The fair market value of property is the price at which it would change hands between a willing and informed buyer and seller. The term is used throughout the Internal Revenue Code, as well as in bankruptcy laws, in many state laws, and by several regulatory bodies.In litigation in many jurisdictions in the United States the fair market value is determined at a hearing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_value_added">Market value added</a></td>
      <td>Market value added (MVA) is the difference between the current market value of a firm and the capital contributed by investors. If MVA is positive, the firm has added value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Value_(economics)">Value (economics)</a></td>
      <td>In economics, economic value is a measure of the benefit provided by a good or service to an economic agent. It is generally measured relative to units of currency, and the interpretation is therefore "what is the maximum amount of money a specific actor is willing and able to pay for the good or service"?</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_capitalization">Market capitalization</a></td>
      <td>Market capitalization, commonly called market cap, is the market value of a publicly traded company's outstanding shares. \nMarket capitalization is equal to the share price multiplied by the number of shares outstanding.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mark-to-market_accounting">Mark-to-market accounting</a></td>
      <td>Mark-to-market (MTM or M2M) or fair value accounting refers to accounting for the "fair value" of an asset or liability based on the current market price, or the price for similar assets and liabilities, or based on another objectively assessed "fair" value.  Fair value accounting has been a part of Generally Accepted Accounting Principles (GAAP) in the United States since the early 1990s, and is now regarded as the "gold standard" in some circles.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitalization-weighted_index">Capitalization-weighted index</a></td>
      <td>A capitalization-weighted (or cap-weighted) index, also called a market-value-weighted index is a stock market index whose components are weighted according to the total market value of their outstanding shares.  Every day an individual stock's price changes and thereby changes a stock index's value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Enterprise_value">Enterprise value</a></td>
      <td>Enterprise value (EV), total enterprise value (TEV), or firm value (FV) is an economic measure reflecting the market value of a business (i.e. as distinct from market price).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_development">Business development</a></td>
      <td>Business development entails tasks and processes to develop and implement growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MYLAN LABORATORIES INC      ITEM 1A Risk Factors             The <font color="blue">following risk <font color="blue">factors could</font></font> have a material adverse effect on our     business, <font color="blue">financial position</font> or results of <font color="blue">operations</font> and could cause the     <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>These <font color="blue">risk factors may</font> not     include all of the <font color="blue">important factors</font> that could affect our business or our     industry  or  that  could cause our <font color="blue">future financial</font> results to differ     <font color="blue"><font color="blue">materially</font> from historic</font> or expected results or cause the <font color="blue">market price</font> of     our <font color="blue">common stock</font> to fluctuate or decline</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________    [72]Table <font color="blue">of <font color="blue">Contents       </font></font>OUR FUTURE REVENUE GROWTH AND PROFITABILITY ARE DEPENDENT UPON OUR ABILITY     TO DEVELOP AND/ OR LICENSE, OR OTHERWISE ACQUIRE, AND INTRODUCE NEW PRODUCTS     ON A TIMELY BASIS IN RELATION TO OUR COMPETITORS’ PRODUCT INTRODUCTIONS OUR     FAILURE TO DO SO SUCCESSFULLY COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR     FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET     VALUE OF OUR COMMON STOCK TO DECLINE             Our <font color="blue">future revenues</font> and <font color="blue">profitability will depend</font>, to a <font color="blue">significant</font>     extent,  upon  our  ability to <font color="blue">successfully</font> develop and/or license, or     otherwise acquire and <font color="blue">commercialize new generic</font> and patent or <font color="blue">statutorily</font>     protected  (usually brand) <font color="blue"><font color="blue">pharmaceutical</font> products</font> in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">development</font> is inherently risky, especially for new drugs for which     safety and efficacy have not <font color="blue">been established</font>, and the market is not yet     proven</td>
    </tr>
    <tr>
      <td>Likewise, <font color="blue">product licensing involves inherent risks</font> including     <font color="blue">uncertainties due</font> to matters that may affect the <font color="blue">achievement</font> of <font color="blue">milestones</font>,     as well as the <font color="blue">possibility</font> of <font color="blue">contractual dis<font color="blue">agreement</font>s with</font> regard to terms     such  as  license  scope  or  <font color="blue">termination</font>  rights</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and     <font color="blue">commercialization</font> process, <font color="blue"><font color="blue">particularly</font> with</font> regard to new drugs, also     requires substantial time, effort and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>We, or a partner,     may not be successful in <font color="blue">commercializing</font> any of the products that we are     developing or licensing (including, without <font color="blue">limitation</font>, nebivolol) on a     timely  basis,  if  at  all,  <font color="blue"><font color="blue">which could</font> <font color="blue">adversely</font> affect</font> our product     <font color="blue">introduction</font> plans, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could     cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>FDA  approval is required before any <font color="blue"><font color="blue">prescription</font> drug product</font>,     including <font color="blue">generic drug products</font>, can be marketed</td>
    </tr>
    <tr>
      <td>The process of obtaining     FDA  approval to <font color="blue">manufacture</font> and <font color="blue">market new</font> and <font color="blue">generic <font color="blue">pharmaceutical</font></font>     products is rigorous, time-consuming, costly and <font color="blue">largely unpredictable</font></td>
    </tr>
    <tr>
      <td>We,     or a partner, may be unable to obtain requisite FDA <font color="blue">approvals on</font> a timely     basis for new generic or brand products that we may develop, license or     otherwise acquire</td>
    </tr>
    <tr>
      <td>Also, for products pending approval, we may obtain raw     materials  or  produce batches of inventory to be used in efficacy and     <font color="blue">bioequivalence</font> testing, as well as in <font color="blue">anticipation</font> of the product’s launch</td>
    </tr>
    <tr>
      <td>In the event that FDA approval is denied or delayed we could be exposed to     the  risk  of this <font color="blue">inventory becoming obsolete</font></td>
    </tr>
    <tr>
      <td>The timing and cost of     obtaining FDA <font color="blue">approvals could <font color="blue">adversely</font> affect</font> our product <font color="blue">introduction</font>     plans, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause the     <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>The ANDA approval process often results in the FDA <font color="blue">granting final</font>     approval to a number of ANDAs for a <font color="blue">given product at</font> the time a patent claim     for a <font color="blue">corresponding</font> brand product or other <font color="blue">market <font color="blue">exclusivity</font> expires</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">often forces us</font> to <font color="blue">face immediate competition</font> when we introduce a generic     <font color="blue">product into</font> the market</td>
    </tr>
    <tr>
      <td>Additionally, ANDA <font color="blue">approvals often continue</font> to be     granted for a <font color="blue">given product subsequent</font> to the <font color="blue">initial launch</font> of the generic     product</td>
    </tr>
    <tr>
      <td>These <font color="blue">circumstances <font color="blue">generally</font></font> result in <font color="blue">significant</font>ly lower prices,     <font color="blue">as well as reduced margins</font>, for <font color="blue"><font color="blue">generic products</font> compared</font> to brand products</td>
    </tr>
    <tr>
      <td>New <font color="blue">generic market entrants <font color="blue">generally</font></font> cause <font color="blue">continued price</font> and margin     <font color="blue">erosion over</font> the <font color="blue">generic product life cycle</font></td>
    </tr>
    <tr>
      <td>The Waxman-Hatch Act provides for a period of 180 days of generic     <font color="blue">marketing <font color="blue">exclusivity</font></font> for each ANDA applicant that is first to file an ANDA     containing   a   <font color="blue">certification</font>   of  <font color="blue">invalidity</font>,  non-<font color="blue">infringement</font>  or     <font color="blue">un<font color="blue">enforceability</font></font> related to a <font color="blue">patent listed <font color="blue">with respect</font></font> to a <font color="blue">reference drug</font>     product, commonly referred to as a <font color="blue">Paragraph IV </font><font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>During this     <font color="blue">exclusivity</font> period, which under <font color="blue">certain circumstances</font> may be required to be     <font color="blue">shared with</font> other applicable ANDA <font color="blue">sponsors with</font> <font color="blue">Paragraph IV </font><font color="blue">certification</font>s,     the  FDA  cannot  grant  <font color="blue">final approval</font> to other ANDA sponsors holding     <font color="blue">applications</font>  for the <font color="blue">same <font color="blue">generic equivalent</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">If an ANDA </font>containing a     <font color="blue">Paragraph IV </font> <font color="blue">certification</font> is successful and the applicant is awarded     <font color="blue">exclusivity</font>, it <font color="blue">generally</font> results in <font color="blue">higher market</font> share, <font color="blue">net revenues</font> and     gross margin for that applicant</td>
    </tr>
    <tr>
      <td>Even if we obtain FDA approval for our     <font color="blue">generic drug products</font>, if we are not the first ANDA applicant to challenge a     <font color="blue">listed patent</font> for such a product, we may lose <font color="blue">significant</font> advantages to a     <font color="blue">competitor</font> that filed its ANDA <font color="blue">containing such</font> a challenge</td>
    </tr>
    <tr>
      <td>The same would     be true in situations where we are required to share our <font color="blue">exclusivity</font> period     with other ANDA <font color="blue">sponsors with</font> <font color="blue">Paragraph IV </font><font color="blue">certification</font>s</td>
    </tr>
    <tr>
      <td>Such situations     could have a material adverse effect on our ability to market that product     profitably and on our <font color="blue">financial position</font> and results of <font color="blue">operations</font>, and the     <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [73]Table <font color="blue">of <font color="blue">Contents       </font></font>OUR APPROVED PRODUCTS MAY NOT ACHIEVE EXPECTED LEVELS OF MARKET ACCEPTANCE,     WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR PROFITABILITY, FINANCIAL     POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR     COMMON STOCK TO DECLINE              Even  if we are able to obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> for our new     <font color="blue"><font color="blue">pharmaceutical</font> products</font>, generic or brand, the success of those products is     <font color="blue">dependent upon market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Levels of market <font color="blue">acceptance</font> for our new     products could be impacted by several factors, including:         •  the <font color="blue">availability</font> of <font color="blue">alternative</font> <font color="blue">products from</font> our <font color="blue">competitor</font>s;         •  the price of our products relative to that of our <font color="blue">competitor</font>s;         •  the timing of our market entry;         •  the ability to market our products <font color="blue"><font color="blue">effective</font>ly</font> to the <font color="blue">retail level</font>; and         •  the <font color="blue">acceptance</font> of our <font color="blue">products by <font color="blue">government</font></font> and <font color="blue">private formularies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">new products</font> may</font>     not achieve expected levels of market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Additionally, continuing     studies of the proper utilization, safety and efficacy of <font color="blue">pharmaceutical</font>     products  are being <font color="blue">conducted by</font> the industry, <font color="blue">government</font> agencies and     others</td>
    </tr>
    <tr>
      <td>Such studies, which increasingly employ sophisticated methods and     <font color="blue">techniques</font>, can <font color="blue">call into question</font> the utilization, safety and efficacy of     <font color="blue">previously marketed products</font></td>
    </tr>
    <tr>
      <td>For example, on July 15, 2005, the FDA issued     a <font color="blue">Public Health Advisory </font>regarding the safe use of <font color="blue">transdermal fentanyl</font>     patches, a product we <font color="blue">currently market</font>, the loss of revenues of <font color="blue">which could</font>     have a <font color="blue">significant</font> impact on our business</td>
    </tr>
    <tr>
      <td>In some cases, studies have     resulted, and may in the future result, in the <font color="blue">discontinuance</font> of product     marketing</td>
    </tr>
    <tr>
      <td>These situations, should they occur, could have a material     adverse effect on our profitability, <font color="blue">financial position</font> and results of     <font color="blue">operations</font>, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>A RELATIVELY SMALL GROUP OF PRODUCTS MAY REPRESENT A SIGNIFICANT PORTION OF     OUR NET REVENUES, GROSS PROFIT OR NET EARNINGS FROM TIME TO TIME IF THE     VOLUME  OR  PRICING OF ANY OF THESE PRODUCTS DECLINES, IT COULD HAVE A     MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF     OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE               Sales  of  a  limited  number of our products often represent a     <font color="blue">significant</font> portion of our <font color="blue">net revenues</font>, gross profit and net earnings</td>
    </tr>
    <tr>
      <td>If     the  volume or pricing of our largest selling <font color="blue">products declines</font> in the     future, our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be     <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font>, and the <font color="blue">market value</font> of our <font color="blue">common stock</font>     <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>WE FACE VIGOROUS COMPETITION FROM OTHER PHARMACEUTICAL MANUFACTURERS THAT     THREATENS THE COMMERCIAL ACCEPTANCE AND PRICING OF OUR PRODUCTS, WHICH COULD     HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND     RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK     TO DECLINE              Our  <font color="blue">competitor</font>s  may be able to develop products and processes     <font color="blue"><font color="blue">competitive</font> with</font> or superior to our own for many reasons, including that     they may have:         •  <font color="blue">proprietary processes</font> or <font color="blue">delivery systems</font>;         •  <font color="blue">larger research</font> and <font color="blue">development</font> and <font color="blue">marketing staffs</font>;         •  <font color="blue">larger production capabilities</font> in a <font color="blue">particular <font color="blue">therapeutic</font> area</font>;         •  more experience in <font color="blue">preclinical testing</font> and <font color="blue">human <font color="blue">clinical trials</font></font>;                                         12       _________________________________________________________________    [74]Table <font color="blue">of <font color="blue">Contents       </font></font>  •  more products; or         •  more experience in developing new drugs and <font color="blue">financial resources</font>,     <font color="blue"><font color="blue">particularly</font> with</font> regard to brand <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Any of these factors and others could have a material adverse effect     on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could     cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>BECAUSE  THE  PHARMACEUTICAL  INDUSTRY  IS  HEAVILY REGULATED, WE FACE     SIGNIFICANT COSTS AND UNCERTAINTIES ASSOCIATED WITH OUR EFFORTS TO COMPLY     WITH APPLICABLE REGULATIONS SHOULD WE FAIL TO COMPLY WE COULD EXPERIENCE     MATERIAL ADVERSE EFFECTS ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF     OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE              The <font color="blue">pharmaceutical</font> industry is subject to <font color="blue">regulation by various</font>     federal and state <font color="blue"><font color="blue"><font color="blue">government</font>al</font> authorities</font></td>
    </tr>
    <tr>
      <td>For instance, we <font color="blue">must comply</font>     with FDA <font color="blue"><font color="blue">requirements</font> <font color="blue">with respect</font></font> to the <font color="blue">manufacture</font>, labeling, sale,     <font color="blue">distribution</font>,  marketing,  <font color="blue">advertising</font>,  promotion  and <font color="blue">development</font> of     <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> FDA and other <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">regulations</font> can result in fines, disgorgement, <font color="blue">unanticipated</font> compliance     <font color="blue">expenditures</font>, recall or seizure of products, total or <font color="blue">partial suspension</font> of     production and/or <font color="blue">distribution</font>, suspension of the FDA’s review of NDAs or     ANDAs, enforcement actions, injunctions and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font><font color="blue">certain circumstances</font>, the FDA also has the authority to <font color="blue">revoke previously</font>     <font color="blue">granted drug approvals</font></td>
    </tr>
    <tr>
      <td>Although we have internal <font color="blue">regulatory</font> compliance     programs and policies and have had a favorable compliance history, there is     no  guarantee  that  these  programs, as currently designed, will meet     <font color="blue"><font color="blue">regulatory</font> agency standards</font> in the future</td>
    </tr>
    <tr>
      <td>Additionally, despite our efforts     at  compliance,  there is no guarantee that we may not be deemed to be     deficient in some manner in the future</td>
    </tr>
    <tr>
      <td>If we were deemed to be deficient in     any  <font color="blue">significant</font>  way, our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> could be <font color="blue"><font color="blue">materially</font> affected</font> and the <font color="blue">market value</font> of our common     stock <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">new drug approval process</font>, the FDA <font color="blue">also regulates</font>     the <font color="blue">facilities</font> and <font color="blue">operational procedures</font> that we use to <font color="blue">manufacture</font> our     products</td>
    </tr>
    <tr>
      <td>We  <font color="blue">must register</font> our <font color="blue">facilities</font> with the FDA All products     <font color="blue">manufacture</font>d in those <font color="blue">facilities</font> must be made in a <font color="blue">manner consistent with</font>     current  good  <font color="blue">manufacturing</font>  practices (“cGMP”)</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with cGMP</font>     <font color="blue">regulations</font> requires substantial <font color="blue">expenditures</font> of time, money and effort in     such  <font color="blue">areas as production</font> and <font color="blue">quality control</font> to ensure full technical     compliance</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">periodically</font> inspects our <font color="blue">manufacturing</font> <font color="blue">facilities</font> for     compliance</td>
    </tr>
    <tr>
      <td>FDA approval to <font color="blue">manufacture</font> a drug is site-specific</td>
    </tr>
    <tr>
      <td>Failure to     comply <font color="blue">with cGMP</font> <font color="blue">regulations</font> at one of our <font color="blue">manufacturing</font> <font color="blue">facilities</font> could     result in an <font color="blue">enforcement action brought by</font> the FDA <font color="blue">which could</font> include     withholding the approval of NDAs, ANDAs or other product <font color="blue">applications</font> of     that  <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If  the  FDA were to require one of our <font color="blue">manufacturing</font>     <font color="blue">facilities</font> to cease or <font color="blue">limit production</font>, our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Delay and cost in obtaining FDA approval to <font color="blue">manufacture</font> at a     <font color="blue">different</font>  <font color="blue">facility</font>  also  could have a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause the     <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>We  are subject, as are <font color="blue">generally</font> all <font color="blue">manufacture</font>rs, to various     federal, state and <font color="blue">local laws regulating</font> working <font color="blue">conditions</font>, as well as     <font color="blue">environment</font>al protection laws and <font color="blue">regulations</font>, including those governing the     discharge of <font color="blue">materials into</font> the <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>Although we have not incurred     <font color="blue">significant</font> costs associated with complying with <font color="blue">environment</font>al provisions in     the past, if changes to such <font color="blue">environment</font>al laws and <font color="blue">regulations</font> are made in     the future that require <font color="blue">significant</font> changes in our <font color="blue">operations</font> or if we     engage in the <font color="blue">development</font> and <font color="blue">manufacturing</font> of <font color="blue">new products</font> requiring new or     <font color="blue">different</font> <font color="blue">environment</font>al controls, we may be required to expend <font color="blue">significant</font>     funds</td>
    </tr>
    <tr>
      <td>Such changes could have a material adverse effect on our business,     <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause the market     value of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________    [75]Table <font color="blue">of <font color="blue">Contents       </font></font>OUR REPORTING AND PAYMENT OBLIGATIONS UNDER THE MEDICAID REBATE PROGRAM AND     OTHER  GOVERNMENTAL PURCHASING AND REBATE PROGRAMS ARE COMPLEX AND MAY     INVOLVE SUBJECTIVE DECISIONS ANY DETERMINATION OF FAILURE TO COMPLY WITH     THOSE OBLIGATIONS COULD SUBJECT US TO PENALTIES AND SANCTIONS WHICH COULD     HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND     RESULTS  OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD     DECLINE             The <font color="blue">regulations</font> regarding reporting and <font color="blue">payment <font color="blue">obligations</font> with</font>     respect  to  Medicaid <font color="blue">reimbursement</font> and rebates and other <font color="blue"><font color="blue">government</font>al</font>     programs are complex, and <font color="blue"><font color="blue">as discussed</font> elsewhere</font> in this Form 10-K, we and     other <font color="blue">pharmaceutical</font> companies are <font color="blue">defendants</font> in a number of <font color="blue">suits filed by</font>     state <font color="blue">attorneys general</font> and have <font color="blue">been notified</font> of an <font color="blue"><font color="blue">investigation</font> by</font> the     US Department  of Justice <font color="blue">with respect</font> to Medicaid <font color="blue">reimbursement</font> and     rebates</td>
    </tr>
    <tr>
      <td>Our <font color="blue">calculations</font> and <font color="blue">methodologies</font> are currently being reviewed     <font color="blue">internally</font>  and  likewise  are  subject to review and <font color="blue">challenge by</font> the     applicable <font color="blue"><font color="blue">government</font>al</font> agencies, and it is possible that <font color="blue">such reviews could</font>     result in material changes</td>
    </tr>
    <tr>
      <td>In addition, because our processes for these     <font color="blue">calculations</font>  and  the <font color="blue">judgments involved</font> in making these <font color="blue">calculations</font>     involve, and <font color="blue">will continue</font> to involve, subjective decisions and complex     <font color="blue">methodologies</font>, these <font color="blue">calculations</font> are subject to the risk of errors</td>
    </tr>
    <tr>
      <td>In addition, as also disclosed in this Form 10-K, a number of state     and  federal  <font color="blue">government</font>  agencies  are  conducting  <font color="blue"><font color="blue">investigation</font>s</font> of     <font color="blue">manufacture</font>rs’ reporting practices <font color="blue">with respect</font> to Average Wholesale Prices     (“AWP”), in which they have suggested that reporting of inflated AWP has led     to  excessive  payments  for <font color="blue"><font color="blue">prescription</font> drugs</font></td>
    </tr>
    <tr>
      <td>We and numerous other     <font color="blue">pharmaceutical</font> companies have been named as <font color="blue">defendants</font> in various actions     relating to <font color="blue">pharmaceutical</font> pricing issues and whether <font color="blue">allegedly</font> improper     actions  by  <font color="blue">pharmaceutical</font> <font color="blue">manufacture</font>rs led to excessive payments by     Medicare and/or Medicaid</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">government</font>al</font> agencies that have commenced, or may commence, an     <font color="blue">investigation</font> of the Company could impose, based on a claim of violation of     fraud and false claims laws or otherwise, civil and/or criminal sanctions,     including fines, penalties and <font color="blue">possible exclusion from federal health care</font>     programs (including <font color="blue">Medicaid and Medicare</font>)</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">applicable laws may</font>     impose  <font color="blue">liability</font>  even  in the absence of <font color="blue">specific intent</font> to defraud</td>
    </tr>
    <tr>
      <td>Furthermore,  <font color="blue">should there</font> be <font color="blue">ambiguity with</font> regard to how to properly     calculate  and  report  payments-and  even  in the absence of any such     ambiguity-a  <font color="blue"><font color="blue">government</font>al</font>  <font color="blue">authority may</font> take a position contrary to a     position we have taken, and may impose civil and/or criminal sanctions</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">such penalties</font> or <font color="blue">sanctions could</font> have a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause the     <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>WE EXPEND A SIGNIFICANT AMOUNT OF RESOURCES ON RESEARCH AND DEVELOPMENT     EFFORTS THAT MAY NOT LEAD TO SUCCESSFUL PRODUCT INTRODUCTIONS FAILURE TO     SUCCESSFULLY  INTRODUCE PRODUCTS INTO THE MARKET COULD HAVE A MATERIAL     ADVERSE  EFFECT  ON  OUR  BUSINESS,  FINANCIAL POSITION AND RESULTS OF     OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE              Much  of  our  <font color="blue">development</font>  effort  is  focused  on <font color="blue">technically</font>     <font color="blue">difficult</font>-to-formulate  products and/or products that require advanced     <font color="blue">manufacturing</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">conduct research</font> and <font color="blue">development</font> primarily to     enable  us  to  <font color="blue">manufacture</font> and market FDA-approved <font color="blue">pharmaceutical</font>s in     <font color="blue">accordance with</font> FDA <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Typically, <font color="blue">research expenses</font> related to the     <font color="blue">development</font> of <font color="blue">innovative compounds</font> and the filing of NDAs are <font color="blue">significant</font>ly     <font color="blue">greater than</font> those <font color="blue">expenses associated with</font> ANDAs</td>
    </tr>
    <tr>
      <td>As we continue to develop     <font color="blue">new products</font>, our <font color="blue">research expenses</font> will likely increase</td>
    </tr>
    <tr>
      <td>Because of the     inherent  <font color="blue">risk associated with research</font> and <font color="blue">development</font> efforts in our     industry,  <font color="blue">particularly</font>  <font color="blue">with respect</font> to new drugs (including, without     <font color="blue">limitation</font>,  nebivolol), our, or a partner’s, research and <font color="blue">development</font>     <font color="blue">expenditures</font> may not result in the successful <font color="blue">introduction</font> of FDA approved     new <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Also, after we submit an NDA or ANDA, the FDA     may request that we <font color="blue">conduct <font color="blue">additional</font> studies</font> and as a result, we may be     unable to <font color="blue">reasonably</font> determine the <font color="blue">total research</font> and <font color="blue">development</font> costs to     develop  a  <font color="blue">particular product</font></td>
    </tr>
    <tr>
      <td>Finally, we cannot be certain that any     <font color="blue">investment</font> made in developing <font color="blue">products will</font> be recovered, even if we are     successful in <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>To the extent that we expend <font color="blue">significant</font>     resources on research and <font color="blue">development</font> efforts and are not able, ultimately,     to introduce successful <font color="blue">new products</font> as a result of those efforts, our     business,                                         14       _________________________________________________________________    [76]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">financial position</font> and results of <font color="blue">operations</font> may be <font color="blue">materially</font> <font color="blue">adversely</font>     affected, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>A  SIGNIFICANT PORTION OF OUR NET REVENUES ARE DERIVED FROM SALES TO A     LIMITED NUMBER OF CUSTOMERS ANY SIGNIFICANT REDUCTION OF BUSINESS WITH ANY     OF THESE CUSTOMERS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS,     FINANCIAL POSITION AND RESULTS OF OPERATIONS, AND THE MARKET VALUE OF OUR     COMMON STOCK COULD DECLINE             A <font color="blue">significant</font> portion of our <font color="blue">net revenues</font> are <font color="blue">derived from sales</font> to a     limited number of customers</td>
    </tr>
    <tr>
      <td>As such, a reduction in or loss of business     <font color="blue">with <font color="blue">one customer</font></font>, or if <font color="blue">one customer</font> were to experience <font color="blue"><font color="blue">difficult</font>y</font> in     <font color="blue">paying us on</font> a <font color="blue">timely basis</font>, our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> could be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font>, and the <font color="blue">market value</font> of     our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>THE USE OF LEGAL, REGULATORY AND LEGISLATIVE STRATEGIES BY COMPETITORS, BOTH     BRAND AND GENERIC, INCLUDING “AUTHORIZED GENERICS” AND CITIZEN’S PETITIONS,     AS WELL AS THE POTENTIAL IMPACT OF PROPOSED LEGISLATION, MAY INCREASE OUR     COSTS ASSOCIATED WITH THE INTRODUCTION OR MARKETING OF OUR GENERIC PRODUCTS,     COULD DELAY OR PREVENT SUCH INTRODUCTION AND/ OR SIGNIFICANTLY REDUCE OUR     PROFIT POTENTIAL THESE FACTORS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR     BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE     MARKET VALUE OF OUR COMMON STOCK TO DECLINE             Our <font color="blue">competitor</font>s, both brand and generic, often pursue strategies to     prevent or delay competition from generic <font color="blue">alternative</font>s to brand products</td>
    </tr>
    <tr>
      <td>These strategies include, but are not limited to:         •  <font color="blue">entering into <font color="blue">agreement</font>s whereby</font> other <font color="blue">generic companies will begin</font> to     market an “<font color="blue">authorized generic</font>”, a <font color="blue">generic equivalent</font> of a branded product,     at the same time <font color="blue">generic competition initially enters</font> the market;         •  filing citizen’s petitions with the FDA, including timing the filings     so  as  to <font color="blue">thwart generic competition by</font> causing delays of our product     approvals;         •  seeking to <font color="blue">establish <font color="blue">regulatory</font></font> and <font color="blue">legal obstacles</font> that would make it     more <font color="blue">difficult</font> to demonstrate <font color="blue">bioequivalence</font>;          •   initiating  <font color="blue">legislative</font>  efforts in various states to limit the     <font color="blue">substitution</font> of <font color="blue">generic versions</font> of brand <font color="blue">pharmaceutical</font>s;         •  <font color="blue">filing suits</font> for <font color="blue">patent <font color="blue">infringement</font></font> that <font color="blue">automatically delay</font> FDA     approval of many <font color="blue">generic products</font>;         •  introducing “next-generation” products prior to the expiration of     market <font color="blue">exclusivity</font> for the reference product, which often <font color="blue">materially</font> reduces     the demand for the <font color="blue">first generic product</font> for which we seek FDA approval;         •  obtaining <font color="blue">extensions</font> of market <font color="blue">exclusivity</font> by conducting clinical     trials of brand drugs in <font color="blue">pediatric populations</font> or by other <font color="blue">potential methods</font>     <font color="blue">as discussed</font> below;         •  persuading the FDA to withdraw the approval of brand name drugs for     which the patents are about to expire, thus allowing the brand name company     to obtain new patented products serving as <font color="blue">substitutes</font> for the products     withdrawn; and         •  seeking to obtain <font color="blue">new patents on drugs</font> for <font color="blue">which <font color="blue">patent protection</font></font> is     about to expire</td>
    </tr>
    <tr>
      <td><font color="blue">The Food and Drug Modernization Act </font>of 1997 includes a pediatric     <font color="blue">exclusivity</font> provision that may provide an <font color="blue">additional</font> six months of market     <font color="blue">exclusivity</font> for <font color="blue">indications</font> of new or <font color="blue">currently market</font>ed drugs if certain     agreed  upon  pediatric  studies are completed by the applicant</td>
    </tr>
    <tr>
      <td><font color="blue">Brand     </font>companies  are  utilizing  this  provision to <font color="blue">extend periods</font> of market     <font color="blue">exclusivity</font></td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [77]Table of <font color="blue"><font color="blue">Contents       </font>    </font>   Some  companies  have  lobbied  <font color="blue">Congress  </font>for <font color="blue">amendments</font> to the     Waxman-Hatch <font color="blue">legislation</font> that would give them <font color="blue">additional</font> advantages over     generic <font color="blue">competitor</font>s</td>
    </tr>
    <tr>
      <td>For example, although the term of a company’s drug     patent can be extended to reflect a portion of the time an NDA is under     <font color="blue"><font color="blue">regulatory</font> review</font>, some companies have <font color="blue">proposed extending</font> the <font color="blue">patent term by</font>     a full year for <font color="blue">each year spent</font> in <font color="blue"><font color="blue">clinical trials</font> rather than</font> the one-half     year that is <font color="blue">currently permitted</font></td>
    </tr>
    <tr>
      <td>If proposals like these were to become <font color="blue">effective</font>, our <font color="blue">entry into</font> the     market and our ability to generate revenues associated with <font color="blue"><font color="blue">new products</font> may</font>     be delayed, reduced or eliminated, <font color="blue">which could</font> have a material adverse     effect on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and     could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>THE INDENTURE FOR OUR SENIOR NOTES AND OUR SENIOR SECURED CREDIT FACILITY     IMPOSE SIGNIFICANT OPERATING AND FINANCIAL RESTRICTIONS, WHICH MAY PREVENT     US FROM CAPITALIZING ON BUSINESS OPPORTUNITIES AND TAKING SOME ACTIONS     THESE  FACTORS  COULD  HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS,     FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET     VALUE OF OUR COMMON STOCK TO DECLINE             The indenture for our <font color="blue">Senior Notes </font>and <font color="blue">senior secured</font> credit <font color="blue">facility</font>     impose  <font color="blue">significant</font>  operating and financial <font color="blue">restrictions</font> on us</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">restrictions</font> will limit the ability of us and our <font color="blue">subsidiaries</font> to, among     other things, incur <font color="blue">additional</font> <font color="blue">indebtedness</font>, make <font color="blue">investment</font>s, sell assets,     incur certain liens, enter into <font color="blue">agreement</font>s restricting our <font color="blue">subsidiaries</font>’     ability to <font color="blue">pay dividends</font>, or merge or <font color="blue">consolidate</font></td>
    </tr>
    <tr>
      <td>In addition, our senior     secured credit <font color="blue">facility</font> requires us to maintain <font color="blue">specified financial ratios</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these <font color="blue">covenants will</font> not <font color="blue">adversely</font> affect our     ability to finance our future <font color="blue">operations</font> or capital needs or to pursue     available business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>A breach of any of these covenants or our     <font color="blue">inability</font>  to maintain the required <font color="blue">financial ratios could</font> result in a     <font color="blue">default under</font> the related <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>If a default occurs, the relevant     lenders could elect to declare the <font color="blue">indebtedness</font>, together with accrued     interest and other fees, to be <font color="blue">immediately due</font> and payable and proceed     against any <font color="blue">collateral securing</font> that <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> have     a material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>OUR ABILITY TO SERVICE OUR DEBT AND MEET OUR CASH REQUIREMENTS DEPENDS ON     MANY FACTORS, SOME OF WHICH ARE BEYOND OUR CONTROL THESE FACTORS COULD HAVE     A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF     OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE             Our ability to satisfy our <font color="blue">obligations</font>, including our <font color="blue">Senior Notes </font>and     our <font color="blue">senior secured</font> credit <font color="blue">facility</font>, will depend on our future operating     performance  and financial results, which will be subject, in part, to     factors beyond our control, including interest rates and general economic,     financial and business <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">generate sufficient</font>     <font color="blue">cash flow</font>, we may be required to: refinance all or a portion of our debt,     including  the  notes  and  our <font color="blue">senior secured</font> credit <font color="blue">facility</font>; obtain     <font color="blue">additional</font>  financing in the future for <font color="blue"><font color="blue">acquisition</font>s</font>, working capital,     capital <font color="blue">expenditures</font> and <font color="blue">general corporate</font> or other purposes; redirect a     substantial portion of our <font color="blue">cash flow</font> to debt service, which as a result,     might not be available for our <font color="blue">operations</font> or other purposes; sell some of     our assets or <font color="blue">operations</font>; reduce or delay capital <font color="blue">expenditures</font>; or revise or     delay our <font color="blue">operations</font> or strategic plans</td>
    </tr>
    <tr>
      <td>If we are required to take any of     these actions, it could have a material adverse effect on our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot assure</font>     you that we would be able to take any of these actions, that these actions     <font color="blue">would enable us</font> to continue to satisfy our <font color="blue">capital <font color="blue">requirements</font></font> or that     these <font color="blue">actions would</font> be <font color="blue">permitted under</font> the terms of our <font color="blue">senior secured</font>     credit  <font color="blue">facility</font>  and the <font color="blue">indenture governing</font> the notes</td>
    </tr>
    <tr>
      <td>The increased     leverage resulting from the financing of our <font color="blue">Dutch Auction </font>self-tender offer     through our notes offering and our <font color="blue">senior secured</font> credit <font color="blue">facility</font> could have     certain material <font color="blue">adverse effects on us</font>, including limiting our ability to     obtain <font color="blue">additional</font> financing and <font color="blue">reducing cash available</font> for our <font color="blue">operations</font>     and  <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>As  a result, our ability to withstand <font color="blue">competitive</font>     pressures  may be decreased and, we may be more vulnerable to economic     downturns, which in turn could reduce our <font color="blue">flexibility</font> in responding to     changing business, <font color="blue">regulatory</font> and economic <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font>     have a material adverse effect on                                         16       _________________________________________________________________    [78]Table <font color="blue">of <font color="blue">Contents       </font></font>our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause     the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>WE DEPEND ON THIRD-PARTY SUPPLIERS AND DISTRIBUTORS FOR THE RAW MATERIALS,     PARTICULARLY THE CHEMICAL COMPOUND(S) COMPRISING THE ACTIVE PHARMACEUTICAL     INGREDIENT, THAT WE USE TO MANUFACTURE OUR PRODUCTS, AS WELL AS CERTAIN     FINISHED GOODS A PROLONGED INTERRUPTION IN THE SUPPLY OF SUCH PRODUCTS     COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND     RESULTS  OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD     DECLINE              We <font color="blue">typically purchase</font> the active <font color="blue">pharmaceutical</font> ingredient (ie the     chemical  compounds that produce the desired <font color="blue">therapeutic</font> effect in our     products) and other materials and supplies that we use in our <font color="blue">manufacturing</font>     <font color="blue">operations</font>,  <font color="blue">as well as certain</font> finished products, from many <font color="blue">different</font>     foreign and <font color="blue">domestic suppliers</font></td>
    </tr>
    <tr>
      <td>Additionally,  we  maintain  <font color="blue">safety stocks</font> in our <font color="blue">raw materials</font>     inventory, and in <font color="blue">certain cases</font> where we have <font color="blue">listed only one supplier</font> in     our <font color="blue">applications</font> with the FDA, have received FDA approval to use <font color="blue">alternative</font>     <font color="blue">suppliers should</font> the need arise</td>
    </tr>
    <tr>
      <td>However, there is no guarantee that we will     always have timely and <font color="blue">sufficient access</font> to a <font color="blue">critical raw</font> material or     finished product</td>
    </tr>
    <tr>
      <td>A <font color="blue">prolonged interruption</font> in the supply of a single-sourced     raw material, including the active ingredient, or finished <font color="blue">product could</font>     cause our <font color="blue">financial position</font> and results of <font color="blue">operations</font> to be <font color="blue">materially</font>     <font color="blue">adversely</font> affected, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">manufacturing</font> capabilities could be <font color="blue">impacted by quality</font>     <font color="blue">deficiencies</font> in the <font color="blue">products which</font> our suppliers provide, <font color="blue">which could</font> have a     material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font>, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">utilizes <font color="blue">controlled substances</font></font> in certain of its current     products  and  products  in  <font color="blue">development</font>  and  therefore must meet the     <font color="blue">requirements</font>  of the <font color="blue">Controlled Substances Act </font>of 1970 and the related     <font color="blue">regulations</font> administered by the Drug Enforcement Administration (“DEA”)</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> relate to the <font color="blue">manufacture</font>, shipment, storage, sale and use     of <font color="blue">controlled substances</font></td>
    </tr>
    <tr>
      <td>The DEA limits the <font color="blue">availability</font> of the active     ingredients  used  in  certain of our <font color="blue">current products</font> and products in     <font color="blue">development</font>  and,  as  a result, our <font color="blue"><font color="blue">procurement</font> quota</font> of these active     <font color="blue">ingredients may</font> not be sufficient to <font color="blue">meet commercial demand</font> or complete     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">must annually apply</font> to the DEA for <font color="blue"><font color="blue">procurement</font> quota</font> in     order  to  obtain these substances</td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">refusal by</font> the DEA in     <font color="blue">establishing</font> our <font color="blue"><font color="blue">procurement</font> quota</font> for <font color="blue">controlled substances</font> could delay or     stop our <font color="blue">clinical trials</font> or product launches, or could cause trade inventory     <font color="blue">disruptions</font> for those products that have already been launched, <font color="blue">which could</font>     have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font>     to decline</td>
    </tr>
    <tr>
      <td>WE  USE  SEVERAL MANUFACTURING FACILITIES TO MANUFACTURE OUR PRODUCTS     HOWEVER, A SIGNIFICANT NUMBER OF OUR PRODUCTS ARE PRODUCED AT ONE LOCATION     PRODUCTION  AT  THIS FACILITY COULD BE INTERRUPTED, WHICH COULD HAVE A     MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF     OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE             Although we have other <font color="blue">facilities</font>, we produce a <font color="blue">significant</font> number of     our <font color="blue">products at</font> our largest <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> disruption     at that <font color="blue">facility</font>, even on a short-term basis, could impair our ability to     produce and <font color="blue">ship products</font> to the <font color="blue">market on</font> a <font color="blue">timely basis</font>, <font color="blue">which could</font> have     a material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [79]Table <font color="blue">of <font color="blue">Contents       </font></font>WE MAY EXPERIENCE DECLINES IN THE SALES VOLUME AND PRICES OF OUR PRODUCTS AS     THE RESULT OF THE CONTINUING TREND TOWARD CONSOLIDATION OF CERTAIN CUSTOMER     GROUPS,  SUCH  AS  THE WHOLESALE DRUG DISTRIBUTION AND RETAIL PHARMACY     INDUSTRIES, AS WELL AS THE EMERGENCE OF LARGE BUYING GROUPS THE RESULT OF     SUCH DEVELOPMENTS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS,     FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET     VALUE OF OUR COMMON STOCK TO DECLINE             We make a <font color="blue">significant</font> amount of our sales to a <font color="blue">relatively</font> small number     of <font color="blue">drug <font color="blue">wholesalers</font></font> and <font color="blue">retail drug chains</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">customers represent</font> an     essential part of the <font color="blue">distribution</font> chain of generic <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Drug <font color="blue">wholesalers</font> and <font color="blue">retail drug chains</font> have undergone, and are continuing     to undergo, <font color="blue">significant</font> consolidation</td>
    </tr>
    <tr>
      <td>This <font color="blue">consolidation may</font> result in     these  groups  gaining <font color="blue">additional</font> purchasing leverage and <font color="blue">consequently</font>     increasing the <font color="blue">product pricing pressures facing</font> our business</td>
    </tr>
    <tr>
      <td>Additionally,     the  emergence  of large buying groups <font color="blue">representing</font> <font color="blue">independent</font> retail     pharmacies and the prevalence and influence of <font color="blue">managed care organizations</font>     and similar <font color="blue">institutions potentially enable</font> those groups to attempt to     <font color="blue">extract price discounts on</font> our products</td>
    </tr>
    <tr>
      <td>The result of these <font color="blue">development</font>s     may have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font>     to decline</td>
    </tr>
    <tr>
      <td>WE MAY BE UNABLE TO PROTECT OUR INTELLECTUAL AND OTHER PROPRIETARY PROPERTY     IN AN EFFECTIVE MANNER, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR     BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE     MARKET VALUE OF OUR COMMON STOCK TO DECLINE             Although our brand <font color="blue">products may</font> have <font color="blue">patent protection</font>, this may not     prevent other <font color="blue">companies from</font> developing <font color="blue">functionally equivalent products</font> or     <font color="blue">from challenging</font> the validity or <font color="blue">enforceability</font> of our patents</td>
    </tr>
    <tr>
      <td>If any     patents  we  use  in  our  business  are  found  or even alleged to be     non-infringed, invalid or not enforceable, we could experience an adverse     effect on our ability to <font color="blue">commercially</font> promote our patented products</td>
    </tr>
    <tr>
      <td>We     could be required to enforce our patent or other <font color="blue">intellectual property</font>     rights through litigation, which can be protracted and involve <font color="blue">significant</font>     expense and an <font color="blue">inherently uncertain outcome</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">negative outcome could</font> have     a material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>OUR COMPETITORS INCLUDING BRAND COMPANIES OR OTHER THIRD PARTIES MAY ALLEGE     THAT WE ARE INFRINGING THEIR INTELLECTUAL PROPERTY, FORCING US TO EXPEND     SUBSTANTIAL RESOURCES IN RESULTING LITIGATION, THE OUTCOME OF WHICH IS     UNCERTAIN ANY UNFAVORABLE OUTCOME OF SUCH LITIGATION COULD HAVE A MATERIAL     ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS     AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE             Companies that produce brand <font color="blue"><font color="blue">pharmaceutical</font> products</font> routinely bring     <font color="blue">litigation against</font> ANDA <font color="blue">applicants</font> that seek FDA approval to <font color="blue">manufacture</font> and     <font color="blue">market generic forms</font> of their <font color="blue">branded products</font></td>
    </tr>
    <tr>
      <td>These companies allege     <font color="blue">patent <font color="blue">infringement</font></font> or other violations of <font color="blue">intellectual property</font> rights as     the  basis for <font color="blue">filing suit against</font> an ANDA applicant</td>
    </tr>
    <tr>
      <td>Likewise, patent     holders may bring <font color="blue">patent <font color="blue">infringement</font></font> suits against companies that are     <font color="blue">currently market</font>ing and selling their approved <font color="blue">generic products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation     </font>often involves <font color="blue">significant</font> expense and can delay or prevent <font color="blue">introduction</font> or     sale of our <font color="blue">generic products</font></td>
    </tr>
    <tr>
      <td>There may also be situations where the Company uses its business     judgment and decides to market and sell products, notwithstanding the fact     that <font color="blue">allegations</font> of <font color="blue">patent <font color="blue">infringement</font></font>(s) have not <font color="blue">been finally resolved by</font>     the courts</td>
    </tr>
    <tr>
      <td>The <font color="blue">risk involved</font> in doing so can be substantial because the     <font color="blue">remedies available</font> to the owner of a patent for <font color="blue">infringement</font> include, among     other things, damages measured by the <font color="blue">profits lost by</font> the <font color="blue">patent owner</font> and     not  by  the <font color="blue">profits earned by</font> the infringer</td>
    </tr>
    <tr>
      <td>In the case of a willful     <font color="blue">infringement</font>, the <font color="blue">definition</font> of which is subjective, such damages may be     trebled</td>
    </tr>
    <tr>
      <td>Moreover, because of the <font color="blue">discount pricing typically involved with</font>     <font color="blue">bioequivalent</font>  products,  patented  brand products <font color="blue">generally</font> realize a     substantially higher profit margin than <font color="blue">bioequivalent</font> products</td>
    </tr>
    <tr>
      <td>An adverse     decision in a <font color="blue">case such as</font> this or in other similar <font color="blue">litigation could</font> have a                                         18       _________________________________________________________________    [80]Table <font color="blue">of <font color="blue">Contents       </font></font>material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>WE  MAY  EXPERIENCE  REDUCTIONS  IN  THE  LEVELS  OF REIMBURSEMENT FOR     PHARMACEUTICAL  PRODUCTS  BY  GOVERNMENTAL  AUTHORITIES, HMOS OR OTHER     THIRD-PARTY PAYERS ANY SUCH REDUCTIONS COULD HAVE A MATERIAL ADVERSE EFFECT     ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD     CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE             Various <font color="blue"><font color="blue"><font color="blue">government</font>al</font> authorities</font> and <font color="blue">private health insurers</font> and other     organizations, such as HMOs, provide <font color="blue">reimbursement</font> to consumers for the cost     of certain <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Demand for our products depends in part     on the extent to which such <font color="blue">reimbursement</font> is available</td>
    </tr>
    <tr>
      <td>Third-party payers     <font color="blue">increasingly challenge</font> the pricing of <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>This trend     and  other  trends  toward the growth of HMOs, <font color="blue">managed health care</font> and     <font color="blue">legislative</font> health care reform create <font color="blue">significant</font> uncertainties regarding     the <font color="blue">future levels</font> of <font color="blue">reimbursement</font> for <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>Further, any     <font color="blue">reimbursement</font> may be reduced in the future, perhaps to the point that market     demand for our <font color="blue">products declines</font></td>
    </tr>
    <tr>
      <td>Such a decline could have a material     adverse effect on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font>     and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>LEGISLATIVE OR REGULATORY PROGRAMS THAT MAY INFLUENCE PRICES OF PRESCRIPTION     DRUGS  COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL     POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR     COMMON STOCK TO DECLINE             Current or future federal or state laws and <font color="blue">regulations</font> may influence     the prices of drugs and, therefore, could <font color="blue">adversely</font> affect the prices that     we receive for our products</td>
    </tr>
    <tr>
      <td>Programs in existence in certain states seek to     set prices of all drugs sold within those states through the regulation and     <font color="blue">administration</font>  of  the sale of <font color="blue"><font color="blue">prescription</font> drugs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Expansion </font>of these     programs, in particular, state Medicaid programs, or changes required in the     way in which Medicaid rebates are calculated under such programs, could     <font color="blue">adversely</font> affect the price we receive for our products and could have a     material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>WE  ARE  INVOLVED  IN VARIOUS LEGAL PROCEEDINGS AND CERTAIN GOVERNMENT     INQUIRIES AND MAY EXPERIENCE UNFAVORABLE OUTCOMES OF SUCH PROCEEDINGS OR     INQUIRIES, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS,     FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET     VALUE OF OUR COMMON STOCK TO DECLINE             We are involved in <font color="blue">various legal <font color="blue">proceedings</font></font> and certain <font color="blue">government</font>     inquiries, including, but not limited to, <font color="blue">patent <font color="blue">infringement</font></font>, product     <font color="blue">liability</font>, breach of contract and claims involving <font color="blue">Medicaid and Medicare</font>     <font color="blue">reimbursement</font>s, some of which are described in our periodic reports and     involve claims for, or the <font color="blue">possibility</font> of fines and <font color="blue">penalties involving</font>,     substantial amounts of money or for other relief</td>
    </tr>
    <tr>
      <td>If any of these legal     <font color="blue">proceedings</font> or inquiries were to result in an adverse outcome, the impact     could have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font>     to decline</td>
    </tr>
    <tr>
      <td>With respect to product <font color="blue">liability</font>, the Company maintains commercial     insurance to <font color="blue">protect against</font> and manage a portion of the <font color="blue">risks involved</font> in     conducting its business</td>
    </tr>
    <tr>
      <td>Although we carry insurance, we believe that no     <font color="blue">reasonable amount</font> of insurance can fully <font color="blue">protect against</font> all such risks     because of the potential <font color="blue">liability</font> inherent in the business of producing     <font color="blue">pharmaceutical</font>s for <font color="blue">human consumption</font></td>
    </tr>
    <tr>
      <td>To the extent that a loss occurs,     depending on the nature of the loss and the level of <font color="blue">insurance coverage</font>     maintained,  it  could have a material adverse effect on our business,     <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause the market     value of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________    [81]Table <font color="blue">of <font color="blue">Contents       </font></font>WE ENTER INTO VARIOUS AGREEMENTS IN THE NORMAL COURSE OF BUSINESS WHICH     PERIODICALLY INCORPORATE PROVISIONS WHEREBY WE INDEMNIFY THE OTHER PARTY TO     THE  AGREEMENT IN THE EVENT THAT WE WOULD HAVE TO PERFORM UNDER THESE     INDEMNIFICATION PROVISIONS, IT COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR     BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE     MARKET VALUE OF OUR COMMON STOCK TO DECLINE              In  the  normal  course of business, we <font color="blue">periodically</font> enter into     <font color="blue">employment</font>,  legal  settlement, and other <font color="blue"><font color="blue">agreement</font>s which incorporate</font>     <font color="blue"><font color="blue">indemnification</font> provisions</font></td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">insurance coverage</font> which we believe     will  <font color="blue"><font color="blue">effective</font>ly</font> mitigate our <font color="blue">obligations</font> under these <font color="blue">indemnification</font>     provisions</td>
    </tr>
    <tr>
      <td>However,  should  our <font color="blue">obligation under</font> an <font color="blue">indemnification</font>     <font color="blue">provision exceed</font> our coverage or <font color="blue">should coverage</font> be denied, our business,     <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">materially</font> affected</font>     and the <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>OUR ACQUISITION STRATEGIES IN GENERAL INVOLVE A NUMBER OF INHERENT RISKS     THESE RISKS COULD CAUSE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL     POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE A DECLINE IN THE MARKET     VALUE OF OUR COMMON STOCK             We <font color="blue">continually seek</font> to expand our <font color="blue">product line through complementary</font>     or strategic <font color="blue"><font color="blue">acquisition</font>s</font> of other companies, products and assets, and     through  joint  ventures,  <font color="blue">licensing <font color="blue">agreement</font>s</font> or other <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Acquisitions, <font color="blue">joint ventures</font> and other business <font color="blue">combinations involve various</font>     inherent  risks,  such  <font color="blue">as assessing accurately</font> the values, strengths,     weaknesses, contingent and other <font color="blue">liabilities</font>, <font color="blue">regulatory</font> compliance and     <font color="blue">potential profitability</font> of <font color="blue">acquisition</font> or other <font color="blue"><font color="blue">transaction</font> candidates</font></td>
    </tr>
    <tr>
      <td>Other inherent risks include the <font color="blue">potential loss</font> of <font color="blue">key personnel</font> of an     acquired  business,  our <font color="blue">inability</font> to achieve identified financial and     operating synergies anticipated to result from an <font color="blue">acquisition</font> or other     <font color="blue">transaction</font> and <font color="blue">unanticipated</font> changes in business and economic <font color="blue">conditions</font>     <font color="blue">affecting</font> an <font color="blue">acquisition</font> or other <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue"><font color="blue">acquisition</font>s</font>,     and other <font color="blue">transaction</font>s, could also be affected by export controls, exchange     rate  <font color="blue">fluctuations</font>,  domestic and foreign political <font color="blue">conditions</font> and the     <font color="blue">deterioration</font> in domestic and foreign economic <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>We may be unable to realize synergies or other benefits expected to     result  from  <font color="blue"><font color="blue">acquisition</font>s</font>,  joint  ventures and other <font color="blue">transaction</font>s or     <font color="blue">investment</font>s we may undertake, or be unable to generate <font color="blue">additional</font> revenue to     offset any <font color="blue">unanticipated</font> <font color="blue">inability</font> to realize these expected synergies or     benefits</td>
    </tr>
    <tr>
      <td><font color="blue">Realization </font>of the anticipated benefits of <font color="blue"><font color="blue">acquisition</font>s</font> or other     <font color="blue">transaction</font>s  could  take  longer  than  expected,  and <font color="blue">implementation</font>     <font color="blue">difficult</font>ies, market factors and the <font color="blue">deterioration</font> in domestic and global     economic  <font color="blue">conditions</font>  <font color="blue">could alter</font> the anticipated benefits of any such     <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> cause a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and could cause a     decline in the <font color="blue">market value</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>OUR FUTURE SUCCESS IS HIGHLY DEPENDENT ON OUR CONTINUED ABILITY TO ATTRACT     AND RETAIN KEY PERSONNEL ANY FAILURE TO ATTRACT AND RETAIN KEY PERSONNEL     COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND     RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK     TO DECLINE             Because our success is <font color="blue">largely dependent on</font> the scientific nature of     our  business,  it  is imperative that we attract and retain qualified     personnel in order to develop <font color="blue">new products</font> and compete <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>If we     fail  to  attract  and  retain key scientific, technical or <font color="blue">management</font>     personnel, our business could be affected <font color="blue">adversely</font></td>
    </tr>
    <tr>
      <td>Additionally, while we     have  <font color="blue">employment</font> <font color="blue">agreement</font>s with certain <font color="blue">key employees</font> in place, their     <font color="blue">employment</font> for the duration of the <font color="blue">agreement</font> is not guaranteed</td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">unsuccessful</font> in retaining all of our <font color="blue">key employees</font>, it could have a material     adverse effect on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font>     and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [82]Table <font color="blue">of <font color="blue">Contents       </font></font>RECENT DECISIONS BY THE FDA, CURRENT BRAND TACTICS AND OTHER FACTORS BEYOND     OUR CONTROL HAVE PLACED OUR BUSINESS UNDER INCREASING PRESSURE, WHICH COULD     HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND     RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK     TO DECLINE             We believe that <font color="blue">certain recent</font> FDA rulings are contrary to multiple     sections of the Federal Food, Drug, and Cosmetic Act and the Administrative     Procedures Act, the FDA’s published <font color="blue">regulations</font> and the <font color="blue">legal precedent on</font>     point</td>
    </tr>
    <tr>
      <td>These decisions <font color="blue">call into question</font> the rules of <font color="blue">engagement</font> in our     industry and have added a level of <font color="blue">unpredictability</font> that may <font color="blue">materially</font>     <font color="blue">adversely</font> affect our business and the <font color="blue">generic industry as</font> a whole</td>
    </tr>
    <tr>
      <td>While we     continue  to challenge these <font color="blue">recent decisions as well as current</font> brand     tactics that <font color="blue">undermine congressional intent</font>, we <font color="blue">cannot guarantee</font> that we     <font color="blue">will prevail</font> or predict when or if these <font color="blue">matters will</font> be rectified</td>
    </tr>
    <tr>
      <td>If they     are not, our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> could     suffer and the <font color="blue">market value</font> of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>WE HAVE BEGUN THE IMPLEMENTATION OF AN ENTERPRISE RESOURCE PLANNING SYSTEM     AS  WITH  ANY IMPLEMENTATION OF A SIGNIFICANT NEW SYSTEM, DIFFICULTIES     ENCOUNTERED  COULD  RESULT IN BUSINESS INTERRUPTIONS, AND COULD HAVE A     MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF     OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE             We have begun the <font color="blue">implementation</font> of an <font color="blue">enterprise resource</font> planning     (“ERP”) system to enhance operating <font color="blue">efficiencies</font> and provide more <font color="blue">effective</font>     <font color="blue">management</font> of our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Implementations of ERP </font>systems and     related software carry <font color="blue">risks such as cost overruns</font>, project delays and     business <font color="blue">interruptions</font> and delays</td>
    </tr>
    <tr>
      <td>If we experience a material business     <font color="blue">interruption as</font> a result of our ERP <font color="blue">implementation</font>, it could have a material     adverse effect on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font>     and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>WE MUST MAINTAIN ADEQUATE INTERNAL CONTROLS AND BE ABLE, ON AN ANNUAL BASIS,     TO PROVIDE AN ASSERTION AS TO THE EFFECTIVENESS OF SUCH CONTROLS FAILURE TO     MAINTAIN ADEQUATE INTERNAL CONTROLS OR TO IMPLEMENT NEW OR IMPROVED CONTROLS     COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND     RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK     TO DECLINE             Effective <font color="blue">internal controls</font> are <font color="blue">necessary</font> for the Company to provide     reasonable assurance <font color="blue">with respect</font> to its financial reports</td>
    </tr>
    <tr>
      <td>We are spending     a  substantial  amount of <font color="blue">management</font> time and resources to <font color="blue">comply with</font>     changing laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>     and <font color="blue">public disclosure</font>, including the Sarbanes-Oxley Act of 2002, new SEC     <font color="blue">regulations</font>  and  the  New  York  Stock Exchange rules</td>
    </tr>
    <tr>
      <td>In particular,     Section 404 of the Sarbanes-Oxley Act of 2002 requires <font color="blue">management</font>’s annual     review and <font color="blue">evaluation</font> of our internal control systems, and <font color="blue">attestations</font> as     to the <font color="blue">effective</font>ness of these <font color="blue">systems by</font> our <font color="blue">independent</font> registered public     <font color="blue">accounting</font>  firm</td>
    </tr>
    <tr>
      <td>If we fail to maintain the adequacy of our internal     controls, we may not be able to ensure that we can conclude on an ongoing     basis that we have <font color="blue">effective</font> <font color="blue">internal control over financial</font> reporting</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">internal control over financial</font> reporting may not prevent or     detect <font color="blue">misstatements</font> because of its inherent <font color="blue">limitation</font>s, including the     <font color="blue">possibility</font> of <font color="blue">human error</font>, the <font color="blue">circumvention</font> or overriding of controls, or     fraud</td>
    </tr>
    <tr>
      <td>Therefore,  even  <font color="blue">effective</font> <font color="blue">internal controls</font> can <font color="blue">provide only</font>     reasonable assurance <font color="blue">with respect</font> to the <font color="blue">preparation</font> and <font color="blue">fair presentation</font>     of <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>In addition, projections of any <font color="blue">evaluation</font> of     <font color="blue">effective</font>ness of <font color="blue">internal control over financial</font> reporting to <font color="blue">future periods</font>     are subject to the risk that the <font color="blue">control may become</font> inadequate because of     changes in <font color="blue">conditions</font>, or that the degree of <font color="blue">compliance with</font> the policies or     <font color="blue">procedures may deteriorate</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the Company </font>fails to maintain the adequacy of     its <font color="blue">internal controls</font>, including any failure to implement required new or     improved  controls,  this  could have a material adverse effect on our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font>, and the <font color="blue">market value</font>     of our <font color="blue">common stock</font> <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [83]Table <font color="blue">of <font color="blue">Contents       </font></font>THERE  ARE INHERENT UNCERTAINTIES INVOLVED IN ESTIMATES, JUDGMENTS AND     ASSUMPTIONS USED IN THE PREPARATION OF FINANCIAL STATEMENTS IN ACCORDANCE     WITH GAAP ANY FUTURE CHANGES IN ESTIMATES, JUDGMENTS AND ASSUMPTIONS USED     OR NECESSARY REVISIONS TO PRIOR ESTIMATES, JUDGMENTS OR ASSUMPTIONS COULD     LEAD TO A RESTATEMENT WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR     BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE     MARKET VALUE OF OUR COMMON STOCK TO DECLINE             The <font color="blue">consolidate</font>d and condensed <font color="blue">consolidate</font>d <font color="blue">financial statements</font>     included  in the periodic reports we file with the SEC are prepared in     <font color="blue">accordance with</font> <font color="blue">accounting</font> principles <font color="blue">generally</font> accepted in the United     States of America (“GAAP”)</td>
    </tr>
    <tr>
      <td>The <font color="blue">preparation</font> of <font color="blue">financial statements</font> in     <font color="blue">accordance with</font> GAAP involves making estimates, judgments and <font color="blue">assumptions</font>     that  affect reported amounts of assets (including <font color="blue">intangible assets</font>),     <font color="blue">liabilities</font>,  revenues,  expenses and income</td>
    </tr>
    <tr>
      <td>Estimates, judgments and     <font color="blue">assumptions</font> are inherently subject to change in the future and any <font color="blue">necessary</font>     revisions to prior estimates, judgments or <font color="blue">assumptions</font> could lead to a     <font color="blue">restatement</font></td>
    </tr>
    <tr>
      <td>Any such changes could result in <font color="blue">corresponding</font> changes to the     amounts  of  assets  (including goodwill and other <font color="blue">intangible assets</font>),     <font color="blue">liabilities</font>, revenues, expenses and income</td>
    </tr>
    <tr>
      <td>Any such changes could have a     material adverse effect on our business, <font color="blue">financial position</font> and results of     <font color="blue">operations</font> and could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
  </tbody>
</table>